Editorial commentary to Narayanan et al. Axonal metabolic recovery in multiple sclerosis patients treated with interferon beta-1b.
Matthews
P M
PM
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D001224:Aspartic Acid / Q000031:analogs & derivatives* / Q000032:analysis; D002986:Clinical Trials as Topic; D020833:Diffuse Axonal Injury / Q000473:pathology*; D018450:Disease Progression; D006801:Humans; D000068556:Interferon beta-1a; D000068576:Interferon beta-1b; D016899:Interferon-beta / Q000494:pharmacology*; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000503:physiopathology; D015203:Reproducibility of Results; D012107:Research Design; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D000068576:Interferon beta-1b; D001224:Aspartic Acid; D016899:Interferon-beta; C000179:N-acetylaspartate; D000068556:Interferon beta-1a